CSPC Innovation Pharmaceutical announced that its controlling subsidiary Giant Stone Biological recently received the "Drug Registration Certificate" for the injection of Omazumab (trade name: En Yitan) issued by the National Medical Products Administration. This pharmaceutical is the first domestically developed biosimilar of Xole (injection of Omazumab) classified as a therapeutic biological product Class 3.3. It is suitable for adult and adolescent (12 years and older) chronic idiopathic urticaria patients who still have symptoms after treatment with H1 antihistamines.